Biotech Insight – Views of Key Opinion Leaders | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

« BIOTECH – Upcoming Conferences

Cancer Diagnosis Revolution: Rubber Lab-on-a-Chip @University of Kansas »

Biotech Insight – Views of Key Opinion Leaders

October 8, 2014 by 2012pharmaceutical

Biotech Insight – Views of Key Opinion Leaders @partnering360.com

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #152: Biotech Insight – Views of Key Opinion Leaders. Published on 10/8/2014

WordCloud Image Produced by Adam Tubman

SOURCE

http://www.partnering360.com/insight#idisplay=20

Biotech Insight @partnering360.com

Gain the insight you need to do better deals. Tune in to partnering360:Insight to view high–profile panels and interviews with leading dealmakers.

Search term(s):

Tag(s):
Biotech
Business development
Deals
Drug development
Drug developmnet
Investment
investors
Medtech
next generation
Next Generation Companies
Pharma
Venture Capital
Select tag(s)

State of the Industry: A focus on the financial landscape in the life sciences

Oct 02, 2014Bruce Booth of Atlas Venture leads this plenary discussion from BioPharm America 2014 with leading investors in the biotech start-up space giving their predictions for 2015.

view full session here

Developing a sustainable commercial model: Can we devise a pricing system for advanced therapies with multiple winners?

Oct 02, 2014Despite the interest and enthusiasm around the therapeutic potential for advanced therapies in a variety of indications, the pricing question remains unanswered.

view full session here

Interview with Gary Nabel, Sanofi

Sep 24, 2014Gary Nabel of Sanofi discusses recent licensing collaboration deals and the key attributes in terms of technology or culture that Sanofi looks for when considering a biotech collaboration.

view full session here

Interview: Ankit Mahadevia – Spero Therapeutics

Sep 24, 2014Ankit Mahadevia, CEO of Spero Therapeutics and a 2014 Fierce 15 winner discusses the value of Spero’s lead technologies and the challenges involved in the development of novel therapies.

view full session here

Interview: Jeffrey Stein – Cidara Therapeutics

Sep 24, 2014Jeffrey Stein, CEO of Cidara Therapeutics, a 2014 Fierce 15 biotech winner, discusses recent incentives in the FDA and Cidara’s efforts in the long-neglected anti-fungal arena.

view full session here

Interview: Annalisa Jenkins – Dimension Therapeutics

Sep 24, 2014At BioPharm America 2014 in Boston, John Carroll, Editor-in-Chief of FierceBiotech, speaks with Annalisa Jenkins, the new CEO of Dimension Therapeutics, a 2014 Fierce 15 biotech winner.

view full session here

Announcement of the Fierce 15

Sep 22, 2014John Carroll, Editor-in-Chief of FierceBiotech, announces the winners of the annual “Fierce 15” leaders in biotech live on site at BioPharm America™ international life science partnering conference in Boston.

view full session here

Vertex builds out BD group with sharp focus on in-licensing

Sep 17, 2014Both at BioPharm America™ in Boston and BIO-Europe^® in Frankfurt, Vertex is on the hunt for research to late-stage development opportunities to further strengthen its pipeline through collaborations, part of a strategic shift meant to complement the ongoing internal research and development programs.

Flagship Ventures explores the pharma innovation supply chain

Sep 09, 2014The care and feeding of the innovation supply chain is a primary focus for Flagship Ventures. While other venture capital firms are focusing on new financing options, this venture firm takes the more holistic approach of fostering innovation among early, disruptive platform companies—many of which they’ve created from scratch in-house—and forging relationships with larger firms that can take the platforms all the way to commercialization.

Sanofi finds innovation in many places

Sep 05, 2014With ten therapeutic areas plus animal health, Sanofi’s R&D portfolio is well balanced to build upon the strengths of each of the franchises in its portfolio and to capitalize on innovative ideas and projects outside the company.

Gene, stem cell therapies bring new players to partnering

Aug 13, 2014The next generation of therapies built upon the science of stem cells and genetics will require new types of partnerships. If there is promise that these technologies can redefine how we understand and treat disease, there is already a certainty that the alliances and partnerships required to bring these therapies to patients are also beyond traditional models for commercialization.

J&J: “Innovation delivers growth and growth sustains our innovation”

Aug 01, 2014″What we are really trying to accomplish is building more than a financial relationship. We are interested in truly finding a way to get to the outcomes. We want to keep our partners intimately involved in a pursuit of truth, in understanding what this science means in the lives of patients who might benefit the most from it. It is this dialogue we are after.”

Deal trends in Regenerative Medicine

Jul 28, 2014The field of regenerative medicine is an up-and-coming new approach for targeting and treating diseases, involving the repair and restoration of previously damaged tissues or organs in the body. According to the Current Agreements life science deals and alliance database, there have been over 700 regenerative medicine/stem cell deals in the last five years alone.

Medtrack Unpartnered Products: Partnerships that could be game changers

Jul 23, 2014As the pharmaceutical landscape continues to consolidate through acquisitions and partnerships, Medtrack Analyst Steven Muntner examines the untapped market of unpartnered products, which represents a potential multi-billion dollar opportunity.

Promethera expands portfolio with progenitor cell platform

Jul 22, 2014Eric Halioua arrives at BioPharm America™ in Boston this September carrying an expanding portfolio of partnering opportunities based on a platform of human liver progenitor cells.

CoStim Pharma: People plus hot science create stunning combo-combo deal

Jul 22, 2014Pathways and platforms are great but true exits come around product portfolios, says Robert Millman, a founder and the chief executive for CoStim Pharmaceuticals, which was snapped up by Novartis just 10 months after the company’s first funding round.

Recent industry analysis on distribution partnering agreements

Jul 21, 2014Recent industry analysis from Current Agreements shows a high volume of dealmaking activity in the distribution deal type among the pharma and biotech companies worldwide.

Interview: Luc Tissot, Tissot Medical Research SA

Jun 16, 2014Luc Tissot of Tissot Medical Research SA discusses their technology to measure the eye pressure that causes glaucoma, and their interest in commercialization partners.

view full session here

Interview: Stéphane Lepretre, Eurasante

Jun 03, 2014Stéphane Lepretre explains Eurasante’s role as an incubator working to promote technology transfer, especially to companies looking to open a facility in the North of France.

view full session here

Interview: Martin Penver, LRQA

Jun 03, 2014Ashley Yeo interviews Martin Penver of Lloyd’s Register Quality Assurance (LRQA) about the timetable for medical device regulation in the EU.

view full session here